Icosapent
CAS 10417-94-4
Icosapent (CAS 10417-94-4) is a Phase 3 pharmaceutical compound with 9 bioactivity targets and 1,992 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 28554.300000000003 nM | 31 | - |
| - | IC50 | 25950 nM | 12 | - |
| - | Potency | 40216.46666666667 nM | 11 | - |
| - | EC50 | 68100 nM | 2 | - |
| - | Kd | 2000 nM | 1 | - |
| - | Ki | 7632 nM | 1 | - |
| Aromatase Enzyme |
IC50 | 4.27 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor |
IC50 | 5.96 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor |
Kd | 5.7 | - | Homo sapiens |
| Retinoic acid receptor RXR-alpha Nuclear hormone receptor |
Ki | 5.12 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor delta Nuclear hormone receptor |
IC50 | 5.4 | - | Homo sapiens |
| Tissue factor Membrane receptor |
IC50 | 4.11 | - | Homo sapiens |
| Prostaglandin G/H synthase 2 Enzyme |
IC50 | 5.15 | - | Ovis aries |
| Prostaglandin G/H synthase 1 Enzyme |
IC50 | 4.89 | - | Bos taurus |
| Oxoeicosanoid receptor 1 GPCR |
IC50 | 5.7 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Rheumatic disorder | 27 | 114.888 | 10072736 |
| Blood immunoglobulin M increased | 20 | 97.363 | 10005601 |
| Blood immunoglobulin A decreased | 20 | 95.421 | 10005585 |
| Colitis microscopic | 28 | 89.628 | 10056979 |
| Cataract operation | 24 | 85.407 | 10063797 |
| Blood immunoglobulin G increased | 20 | 81.112 | 10005596 |
| Multiple allergies | 27 | 77.141 | 10028164 |
| Skin reaction | 27 | 70.468 | 10040914 |
| Hernia | 27 | 68.398 | 10019909 |
| Glaucoma | 28 | 67.622 | 10018304 |
| Hepatic enzyme abnormal | 21 | 65.843 | 10062685 |
| Multiple fractures | 20 | 61.041 | 10028200 |
| Drug-induced liver injury | 36 | 60.915 | 10072268 |
| Eye disorder | 27 | 58.535 | 10015916 |
| Sciatica | 28 | 55.078 | 10039674 |
| Cataract | 34 | 51.112 | 10007739 |
| Myelosuppression | 27 | 51.068 | 10028584 |
| Diverticulitis | 29 | 48.541 | 10013538 |
| Platelet count decreased | 50 | 48.242 | 10035528 |
| Immunodeficiency | 22 | 47.772 | 10061598 |
| Red blood cell sedimentation rate increased | 27 | 44.857 | 10049187 |
| Prescribed underdose | 22 | 39.726 | 10073085 |
| Blood glucose increased | 36 | 38.873 | 10005557 |
| Psoriatic arthropathy | 32 | 37.852 | 10037162 |
| White blood cell count decreased | 43 | 37.066 | 10047942 |
| Anaphylactic reaction | 29 | 35.208 | 10002198 |
| Blood alkaline phosphatase increased | 24 | 32.049 | 10059570 |
| Gamma-glutamyltransferase increased | 22 | 30.74 | 10017693 |
| Herpes zoster | 29 | 30.667 | 10019974 |
| Musculoskeletal pain | 29 | 30.15 | 10028391 |
| Cerebral infarction | 20 | 29.645 | 10008118 |
| Cystitis | 22 | 29.37 | 10011781 |
| Bronchitis | 32 | 28.293 | 10006451 |
| C-reactive protein abnormal | 20 | 27.677 | 10068559 |
| Blood creatine phosphokinase MM increased | 4 | 27.659 | 10005477 |
| C-reactive protein increased | 30 | 26.464 | 10006825 |
| Mobility decreased | 30 | 26.239 | 10048334 |
| Blood pressure increased | 40 | 26.11 | 10005750 |
| Drug resistance | 19 | 25.822 | 10059866 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ICOSAPENT | 90 | SU | MTHSPL |
| Icosapent | 90 | SU | MTHSPL |
| icosapent | 90 | SU | MTHSPL |
| eicosapentaenoic acid | 90 | PIN | RXNORM |
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Arthralgia | eicosapentaenoic | LLT | C0003862 |
| Arthralgia | eicosapentaenoic | PT | C0003862 |
| Musculoskeletal discomfort | eicosapentaenoic | PT | C0948594 |
| Oropharyngeal pain | eicosapentaenoic | LLT | C2363731 |
| Oropharyngeal pain | eicosapentaenoic | PT | C2363731 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Icosapent used for in pharmaceutical contexts?
Icosapent (CAS 10417-94-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Icosapent?
Icosapent has 1,992 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Rheumatic disorder, Blood immunoglobulin M increased, Blood immunoglobulin A decreased, Colitis microscopic, Cataract operation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Icosapent also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Eicosapentaenoic Acid with EU status "permitted".
What clinical phase is Icosapent in?
Icosapent is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Icosapent?
Icosapent has 15 bioactivity rows in this page query. Rendered target entries include Aromatase, Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma, Retinoic acid receptor RXR-alpha, Peroxisome proliferator-activated receptor delta.